Sun Pharma to Acquire Organon for $11.75 Billion in Major Women's Health and Biosimilars Expansion

Sun Pharmaceutical Industries LimitedSearch company has entered into a definitive agreement to acquire Organon & Co.Search company for $14.00 per share in an all-cash transaction with an enterprise valuation of $11.75 billion, marking one of the largest pharmaceutical acquisitions in recent years and significantly expanding Sun Pharma's global footprint in women's health and biosimilars.

Strategic Transformation Through Acquisition

The acquisition represents a transformative deal for Sun Pharma, positioning the combined entity among the top 25 global pharmaceutical companies with combined revenue of $12.4 billion. Upon completion, Sun Pharma will become a leading player in established brands and branded generics, with innovative medicines comprising 27% of revenue share.

"This transaction represents a significant opportunity for Sun Pharma to build on its vision of Reaching People and Touching Lives," said Dilip Shanghvi, Executive Chairman of Sun Pharma. "Organon's portfolio, capabilities and global reach are highly complementary to our own, and we believe that bringing the two organizations together can create a stronger and more diversified platform."

Organon's Strategic Value

Organon, formed through a spinoff from MerckSearch company in 2021, brings a portfolio of more than 70 products across women's health and general medicines, including biosimilars, commercialized across 140 countries. The company's largest markets include the United States, Europe, China, Canada, and Brazil, supported by six manufacturing facilities across the European Union and emerging markets.

The acquisition will establish Sun Pharma as a top 3 company in global women's health, creating a commercial platform for future growth. Additionally, the deal enables Sun Pharma's entry into biosimilars as the 7th largest global biosimilar player, significantly diversifying its therapeutic portfolio.

Financial Performance and Market Expansion

For the year ended December 31, 2025, Organon reported $6.2 billion in revenue and adjusted EBITDA of $1.9 billion. The company maintains debt of $8.6 billion and a cash balance of $574 million. Organon recently completed a product divestiture for an upfront payment of $440 million, with net proceeds contributing to its March 31, 2026 cash balance.

The combined entity will operate in 150 countries with 18 large markets each generating over $100 million in revenues. The transaction is expected to create a stronger cash-generating company with EBITDA and cash flow set to nearly double, supporting deleveraging from a post-transaction net debt/EBITDA ratio of 2.3x.

Integration Strategy and Timeline

Kirti Ganorkar, Managing Director of Sun Pharma, outlined the integration priorities: "Our immediate priorities will be business continuity, disciplined integration and responsible value creation. We see strong potential in leveraging Organon's talent pool. In addition, there is a scope for synergies including significant revenue upside opportunities to be realized over the coming years."

The transaction has received approval from the boards of directors of both companies and is subject to customary closing conditions, including regulatory approvals and Organon stockholder approval. The deal is expected to close in early 2027.

Stakeholder Perspectives

Carrie Cox, Executive Chair of Organon, commented on the strategic rationale: "Following a comprehensive review of strategic alternatives, our Board determined that this all-cash transaction offers compelling and immediate value to Organon stockholders. We believe Sun Pharma is well positioned to support Organon's businesses, employees and patients globally, and to further advance our commitment to delivering impactful medicines and solutions."

Transaction Structure and Financing

Sun Pharma will acquire 100% of Organon's issued and outstanding shares through a merger structure, with Organon surviving the merger. The acquisition will be funded through a combination of available cash resources and committed financing from banks, including Citigroup Global Markets Asia Ltd.Search company, JPMorgan Chase Bank, N.A.Search company, and MUFG Bank, Ltd.Search company

The transaction involves comprehensive advisory support, with J.P. Morgan Securities LLCSearch company and Jefferies LLCSearch company serving as financial advisors to Sun Pharma, while Morgan Stanley & Co. LLCSearch company serves as lead financial advisor to Organon, with Goldman Sachs & Co. LLCSearch company providing additional financial advisory services.